158326-77-3

Usage

Uses

Used in Medicinal Chemistry:
7-bromo-4,4-dimethyl-1,2,3,4-tetrahydroquinoline is used as a compound in medicinal chemistry for its potential biological activity. Its unique structure allows it to be a candidate for the development of new drugs, particularly in the area of pharmaceutical research.
Used in Drug Discovery:
In drug discovery, 7-bromo-4,4-dimethyl-1,2,3,4-tetrahydroquinoline is utilized as a starting material or a scaffold for the design and synthesis of novel therapeutic agents. Its structural features make it a promising candidate for further modification and optimization to enhance its pharmacological properties.
Used in Organic Synthesis:
7-bromo-4,4-dimethyl-1,2,3,4-tetrahydroquinoline is used as an intermediate in organic synthesis for the preparation of other functionalized quinoline derivatives. Its presence in the synthesis process can lead to the creation of a variety of compounds with different applications in various fields.
Used in Pharmaceutical Research:
In pharmaceutical research, 7-bromo-4,4-dimethyl-1,2,3,4-tetrahydroquinoline is employed as a compound with potential applications in the development of new medications. Its unique structural features and biological activity make it a valuable asset in the search for innovative therapeutic solutions.

Upstream product

• 591-19-5 m-Bromoaniline 
• 3350-78-5 3,3-Dimethylacryloyl chloride 
• 129790-04-1 N-(3-bromophenyl)-3,3-dimethyl-acrylamide 
• 185316-44-3 7-bromo-4,4-dimethyl-3,4-dihydroquinolin-2(1H)-one 

Downstream Products

• 205750-58-9 4,4-dimethyl-1,2,3,4-tetrahydro-N-(4-methylphenyl)-7-bromoquinoline 
• 158326-65-9 7-Cyano-3,4-dihydro-4,4-dimethyl-N-phenyl-1(2H)-quinolinecarboxamide 
• 198696-11-6 4-(1-Isopropyl-4,4-dimethyl-1,2,3,4-tetrahydro-quinolin-7-ylethynyl)-benzoic acid ethyl ester 
• 198696-09-2 4-(4,4-Dimethyl-1,2,3,4-tetrahydro-quinolin-7-ylethynyl)-benzoic acid ethyl ester 

Relevant academic research and scientific papers

Inhibitors Targeting STAT5 Signaling in Myeloid Leukemias: New Tetrahydroquinoline Derivatives with Improved Antileukemic Potential

Signal transducers and activators of transcription 5A and 5B (STAT5A and STAT5B) are two closely related STAT family members that are crucial downstream effectors of tyrosine kinase oncoproteins such as FLT3-ITD in acute myeloid leukemia (AML) and BCR-ABL

N-aryl substituted tetrahydroquinolines having retinoid agonist, retinoid antagonist or retinoid inverse agonist type biological activity

Compounds of the formula STR1 where the symbols have the meaning defined in the specification, have retinoid, retinoid antagonist or retinoid inverse agonist-like biological activity.

Synthesis and biological activity of 1,2,3,4-tetrahydroquinoline and 3,4-(1H)-dihydroquinolin-2-one analogs of retinoic acid

Retinoids are natural and synthetic analogs of the hormone retinoic acid. Retinoids are currently being investigated clinically as drugs in several areas, including dermatology and oncology. We report the synthesis and biological activity of a new series of potent, RAR-specific retinoids substituted with a 1,2,3,4-tetrahydroquinoline or a 3,4-1H)-dihydroquinolin-2-one group.

Cardioselective antiischemic ATP-sensitive potassium channel openers. 4. Structure-activity studies on benzopyranylcyanoguanidines: Replacement of the benzopyran portion

The results of our efforts aimed at the replacement of the benzopyran ring of the lead cardiac selective antiischemic ATP-sensitive potassium channel (K(ATP)) opener (4) are described. Systematic modification of the benzopyran ring of 4 resulted in the discovery of a structurally simpler acyclic analog (8) with slightly lower antiischemic potency than the lead compound 4. Further structure-activity studies on the acyclic analog 8 provided the 2- phenoxy-3-pyridylurea analog 18 with improved antiischemic potency and selectivity compared to the benzopyran-based compound 4. These data demonstrate that the benzopyran ring of 4 and its congeners is not mandatory for antiischemic activity and cardiac selectivity. The results described in this paper also show that, as for the benzopyran class of compounds, the structure-activity relationships for the antiischemic and vasorelaxant activities of K(ATP) openers are distinct. The mechanism of action of the acyclic analogs (e.g., 18) still appears to involve K(ATP) opening as their cardioprotective effects are abolished by pretreatment with the K(ATP) blocker glyburide.